Article Text

Download PDFPDF
CASE REPORT
Topical timolol for the treatment of pyoderma gangrenosum
  1. Catarina Moreira1,2,
  2. Sofia Lopes1,
  3. Maria João Cruz1,2,
  4. Filomena Azevedo1
  1. 1Centro Hospitalar São João, Porto, Portugal
  2. 2Faculty of Medicine, University of Porto, Porto, Portugal
  1. Correspondence to Dr Catarina Moreira, cat_moreira{at}icloud.com

Summary

Treatment of pyoderma gangrenosum (PG) remains a challenge, and there are currently no specific or uniformly effective therapies. Although widespread or rapidly progressive disease often requires systemic treatment, localised and mild lesions may be effectively controlled with topical agents. The most frequently applied topical drugs are corticosteroids and calcineurin inhibitors. Recently, a patient with idiopathic PG of the lower limb was successfully treated with topical timolol and collagenase. Here, we report a case of a patient with collagenous colitis, ankylosing spondylitis and periumbilical PG. Persistent ulcerated skin lesions were successfully treated with topical timolol, although a flare of the underlying bowel disease temporarily interrupted the improvement. The case presented enhances the previously reported therapeutic potential of topical timolol in the treatment of PG. Control of chronic underlying disorders is critical to prevent rebound flares and maintain the benefit.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors CM contributed to the conception and design of the work and the acquisition of data, reviewed the literature and drafted the article. SL, MJC and FA contributed to the conception and design of the work, the acquisition of data and provided critical revision of the article. All authors provided final approval of the version to publish and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.